Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
about
Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeGenetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Sequential CCR5-Tropic HIV-1 Reactivation from Distinct Cellular Reservoirs following Perturbation of Elite Control.Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino TerminusProviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoirLack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.Defective proviruses rapidly accumulate during acute HIV-1 infectionBroad activation of latent HIV-1 in vivo.Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.HIV-1 Reservoirs During Suppressive Therapy.Persistent HIV-1 replication during antiretroviral therapy.The Alphabet Soup of HIV Reservoir Markers.Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.No evidence of HIV replication in children on antiretroviral therapy.Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.HIV: Persistence through division.Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.Challenges in HIV-persistent viral replication regardless of potent antiretroviral therapy.HIV dynamics linked to memory CD4+ T cell homeostasis.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.What do we measure when we measure cell-associated HIV RNA.HIV evolution and diversity in ART-treated patients.Blood biomarkers of expressed and inducible HIV-1.Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.No evidence of ongoing evolution in replication competent latent HIV-1 in a patient followed up for two years.Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.Phylogenetic approach to recover integration dates of latent HIV sequences within-hostInsight into treatment of HIV infection from viral dynamics models
P2860
Q33442370-A77F11DE-1B13-4FB0-AE49-5246CF653F2AQ33693987-0B4755EA-DB87-4AB6-AA06-CDA3DAE2A571Q34531858-384A45FD-31A0-4A89-9E51-72837B09ECB9Q36073706-CADF8B74-E6CD-4CBB-B314-21AA38A1E3E4Q36195192-2DB3030C-7075-4A70-8DE4-661A8EAC0103Q36318184-9E269CE8-9445-4E76-80B6-201F33198254Q37145779-EAB11D86-B4B0-45A7-A615-44CE2435D880Q37161557-83B17FD9-BC32-4493-9144-6772F4804D33Q37239064-31028719-A1C8-4B60-A5DF-AB95551D4648Q37260309-172E94D3-1E52-41F5-AFD4-EFBFCA54781DQ37624842-C34F54D1-2A99-486D-B5D0-AF0E519AF054Q37656766-01B35CF8-9CC9-426F-984F-3D64EF3A6FF6Q38808266-97A3883B-460B-4DD9-872E-83BADFE7D6DDQ39237000-9BF2FDEA-306E-4C86-94C5-08F7028006CAQ39362365-855AA33D-B71C-48B9-AA12-7751D3B00888Q40047983-DDBA6161-1554-43D9-8E10-F726B36B6564Q40239429-1B061BDC-842C-4CEC-9FA9-C47EC94F09E5Q40271315-1226CEDD-4498-4354-B53E-DEE064CCBB30Q40279377-5F3E7B7C-6237-4F0A-8C9C-9C7577EA71DDQ40835775-8AF1EC7B-E5D3-4FEB-BD0E-B1331C5E4C69Q44555364-2894AF03-8705-45A4-BAA6-34E39841610FQ45326424-B80DF542-0C19-4C0C-AE05-941AC4A178FBQ45979839-F6F06656-DDE6-4706-A80E-33F540A2593DQ47548192-A9962E26-3BA8-4342-99EB-B5C31A7E273EQ47548221-03453EEC-69F5-44C2-97BE-D2173DE96510Q47553595-5A33EFAD-4585-48EC-85C2-DA09FECCD4ABQ47585986-07B6B312-9A57-4361-A51F-64A3F231C994Q48113493-65AA451C-17CB-4500-B20E-DDC558A77FD7Q49354408-0D2058C4-DCF0-4886-A4D6-13AFC9B1D709Q52657975-2DD033F6-0D4E-4F05-BE4E-598514332591Q58762598-C2B55EF6-55DC-4CB4-A9BD-EFC64BA96A0AQ58788145-090FDDF1-14FE-407B-955A-D3874CD47812
P2860
Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@ast
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@en
type
label
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@ast
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@en
prefLabel
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@ast
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@en
P2093
P2860
P356
P1433
P1476
Origin of Rebound Plasma HIV I ...... ing of Antiretroviral Therapy.
@en
P2093
Ann Wiegand
John M Coffin
John W Mellors
Jonathan Z Li
Michael Lederman
Rajesh T Gandhi
P2860
P304
P356
10.1128/JVI.02139-15
P407
P577
2015-11-18T00:00:00Z